Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. uri icon

Overview

publication date

  • October 26, 2018

Research

keywords

  • Bortezomib
  • Mutation
  • Receptors, CXCR4
  • Waldenstrom Macroglobulinemia

Identity

PubMed Central ID

  • PMC6293872

Scopus Document Identifier

  • 85058494001

Digital Object Identifier (DOI)

  • 10.1182/blood-2018-07-863241

PubMed ID

  • 30366921

Additional Document Info

volume

  • 132

issue

  • 24